---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-005554"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:30:57.243197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma Q4 net loss $8.4M, revenue $48.4M; cash $710.3M

## Summary
- Q4 2022 net loss $8.4M (vs $83.7M Q4 2021); full year net loss $183.1M (vs $250.2M).
- Revenue $48.4M in Q4 2022, up from $2.8M in Q4 2021, driven by GSK collaboration deferred revenue.
- Cash, cash equivalents and marketable securities $710.3M as of Dec 31, 2022; cash runway into 2026.
- Phase 1 trials ongoing for LYL797 (ROR1 CAR T) and LYL845 (TIL); initial data expected in 2024.
- Lynn Seely named President and CEO in Dec 2022; Rahsaan Thompson CLO; Gary Lee CSO.

## SEC filing metadata
- accession: 0001628280-23-005554
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/lyel-20230228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-005554
- JSON: https://secwatch.observer/filing/0001628280-23-005554.json
- Plain text: https://secwatch.observer/filing/0001628280-23-005554.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported the year ended December 31, 2022 results: net income $183.1 million.
  - Period: the year ended December 31, 2022
  - Net income: $183.1 million
  - Result: reported results
  source text: Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm
- Earnings Releases
  Lyell Immunopharma, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.4 million.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: $8.4 million
  - Result: reported results
  source text: Lyell reported a net loss of $8.4 million and $183.1 million for the fourth quarter and year ended December 31, 2022,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828023005554/0001628280-23-005554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.